Century Therapeutics announced the appointment of Daphne Quimi and Timothy Walbert to the Company's Board of Directors. Ms. Quimi is currently Chief Financial Officer of Amicus Therapeutics and brings experience in public accounting and financial reporting to Century. Mr. Walbert is currently Chairman, President, and Chief Executive Officer of Horizon Therapeutics, and brings expertise in product portfolio building and commercialization.

In conjunction with these new appointments, Century also announced that Eli Casdin, Chief Investment Officer of Casdin Capital, has resigned from the Board of Directors, effective as of October 1, 2022. Before serving as Amicus's Chief Financial officer, Ms. Quimi was Amicus's Senior Vice President, Finance and Corporate Controller. Ms. Quimi is currently a member of the Board of Directors at Amylyx Pharmaceuticals.

Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Earlier in her career she worked for KPMG.

Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B. A from the Stern School of Business of New York University. In addition to his current role of President and Chief Executive Officer of Horizon Therapeutics, Mr. Walbert has served as Chairman of Horizon's Board of Directors since 2010. Before joining Horizon, Mr. Walbert served as President, Chief Executive Officer and Director of IDM Pharma Inc., and also held prior senior roles at NeoPharm Inc., Abbott (AbbVie), G.D. Searle & Company, Merck & Co.

Inc. and Wyeth. Mr. Walbert received a B.A. in Business from Muhlenberg College.